HARBIN, China, Dec. 6, 2011 /PRNewswire-Asia-FirstCall/ -- From
December 1-3, 2011, Weikang
participated in China's 66th
National Drug Trade Fair held in Zhengzhou, the capital of Henan Province. Weikang had two booths staffed
by 16 people participating in the fair. During the fair, Weikang
reached or extended various agreements with distributors.
Mr. Wang, the Chairman and CEO of Weikang commented: "We are
very glad about the effect of participating in this fair, which is
the largest drug fair with the longest history in China. Weikang has always participated in this
fair in recent years and each time it has been a major channel of
promotion for our products." Mr. Wang continued, "We not only
secured distribution agreements, but also greatly promoted the
image of our products in the marketplace, which we believe will
lead to more distribution contracts in the future."
About China's 66th
National Drug Trade Fair:
The fair is known as the largest drug trade fair in China. This year it covered a 65,000 square
meter area, with 3200 booths and more than 2000 companies
participating. The total number of professionals that visited the
fair this year reached 100,000.
About Weikang Bio-Technology Group Co., Inc.
Weikang Bio-Technology Group Co., Inc. is principally engaged in
developing, manufacturing and distributing Traditional Chinese
Medicine (TCM), and health and nutritional supplements in
China, in compliance with
requisite Chinese licenses and approvals. The Company is also
expanding its business scope to develop, manufacture and distribute
Chinese herbal extract products and GMP certified western
prescription and OTC pharmaceuticals through its acquisition of
Tianfang Pharmaceutical Co., Ltd. For more information,
please visit http://www.weikangbio.com.
Safe Harbor Statement
Certain statements in this press release constitute
forward-looking statements for purposes of the safe harbor
provisions under The Private Securities Litigation Reform Act of
1995. These forward-looking statements are often identified
by the use of forward-looking terminology such as "believes,"
"expects" or similar expressions, involve known and unknown risks
and uncertainties. Although the Company believes that the
expectations reflected in these forward-looking statements are
reasonable, they do involve assumptions, risks and uncertainties,
and these expectations may prove to be incorrect. You should not
place undue reliance on these forward-looking statements, which
speak only as of the date of this press release. The Company's
actual results could differ materially from those anticipated in
these forward-looking statements as a result of a variety of
factors, including those discussed in the Company's periodic
reports that are filed with the Securities and Exchange Commission
and available on its website (http://www.sec.gov).
All forward-looking statements attributable to the Company or
persons acting on its behalf are expressly qualified in their
entirety by these factors. Other than as required under the
securities laws, the Company does not assume a duty to update these
forward-looking statements.
SOURCE Weikang Bio-Technology Group Co., Inc.